Dataset Information


SRS endotype assignment of septic shock patients from the VANISH randomised trial

ABSTRACT: The aim of the experiment was to assign patients enrolled in the VANISH randomised trial to sepsis response signature (SRS) endotypes based on a previously published gene expression signature, in order to test for differential responses to treatment. VANISH was a double-blind randomised clinical trial in septic shock, with patients randomised to receive norepinephrine or vasopressin followed by hydrocortisone or placebo. We collected blood samples upon enrolment, extracted RNA and performed transcriptomic profiling using microarrays, allocated patients to SRS1 or SRS2 using a linear model (Davenport 2016), and tested for an association between sepsis endotype and response to either norepinephrine or vasopressin, or to corticosteroids. There was a significant interaction between treatment with hydrocortisone or placebo, and SRS endotype (p=0·02)

ORGANISM(S): Homo sapiens  

SUBMITTER: Katie L Burnham   David Antcliffe  

PROVIDER: E-MTAB-7581 | ArrayExpress | 2018-12-18


altmetric image


Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial.

Antcliffe David B DB   Burnham Katie L KL   Al-Beidh Farah F   Santhakumaran Shalini S   Brett Stephen J SJ   Hinds Charles J CJ   Ashby Deborah D   Knight Julian C JC   Gordon Anthony C AC  

American journal of respiratory and critical care medicine 20190401 8

RATIONALE:There remains uncertainty about the role of corticosteroids in sepsis with clear beneficial effects on shock duration, but conflicting survival effects. Two transcriptomic sepsis response signatures (SRSs) have been identified. SRS1 is relatively immunosuppressed, whereas SRS2 is relatively immunocompetent. OBJECTIVES:We aimed to categorize patients based on SRS endotypes to determine if these profiles influenced response to either norepinephrine or vasopressin, or to corticosteroids i  ...[more]

Similar Datasets

2010-12-09 | E-GEOD-19938 | ArrayExpress
2012-03-01 | E-GEOD-34225 | ArrayExpress
2017-12-15 | PXD005454 | Pride
2016-07-01 | E-GEOD-79573 | ArrayExpress
2014-01-10 | E-MTAB-1598 | ArrayExpress
| GSE77791 | GEO
| GSE95007 | GEO
2007-10-06 | E-GEOD-5953 | ArrayExpress
| GSE60093 | GEO
2018-10-26 | PXD005792 | Pride